Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Nordisk’s Obesity Drug Wins FDA Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Novo Nordisk’s Obesity Drug Wins FDA Approval

First once-daily human (GLP-1) analogue shown to result in greater weight loss

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novo Nordisk has received approval from the FDA for its NDA for Saxenda(R) (liraglutide 3mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity. Saxenda is indicated as an adjunct to a reduced-calorie diet and exercise for chronic weight management in obese adults (BMI =>30 kg/m2) or who are overweight (BMI =>27 kg/m2) with at least one weight-related comorbidity such as type 2 diabetes and cardiovascular disease.
 
The Phase III SCALE (Satiety and Clinical Adiposity−Liraglutide Evidence in Non-diabetic and Diabetic adults) clinical program included more than 5,000 study participants who have obesity or were overweight with comorbidities.Trial data showed that Saxenda, in combination with a reduced-calorie diet and increased physical activity, resulted in significantly greater weight loss than diet and physical activity alone.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters